The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer Lei GuYidong XuZhongchen Liu PHASE I STUDIES 19 March 2019 Pages: 221 - 228
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a Jianguo BaiJianfei WuWei Yang PRECLINICAL STUDIES 11 April 2019 Pages: 229 - 245
Midkine silencing enhances the anti–prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB Suat ErdoganKader TurkekulAyhan Bilir PRECLINICAL STUDIES 16 April 2019 Pages: 246 - 263
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma Yen-Bin HsuMing-Chin LanMing-Ying Lan PRECLINICAL STUDIES 16 April 2019 Pages: 264 - 273
Anticancer activity, apoptosis and a structure–activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides Kevin W. WellingtonNatasha I. KolesnikovaLesetja R. Motadi PRECLINICAL STUDIES 27 April 2019 Pages: 274 - 286
Identification of a 3,3-difluorinated tetrahydropyridinol compound as a novel antitumor agent for hepatocellular carcinoma acting via cell cycle arrest through disturbing CDK7-mediated phosphorylation of Cdc2 Wu BiJi-chang XiaoPeng-fei Zhang PRECLINICAL STUDIES 11 May 2019 Pages: 287 - 298
Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide Javier MegíasAlba MartínezMiguel Cerdá-Nicolás PRECLINICAL STUDIES 11 May 2019 Pages: 299 - 310
Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling Lei ZhangQiaoling SongChenyang Zhao PRECLINICAL STUDIES 14 May 2019 Pages: 311 - 320
Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression Qiubo ZhangXuanna LiKaihong Huang PRECLINICAL STUDIES 14 May 2019 Pages: 321 - 328
Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway Gaochao HouXiang YuanXianli Liu PRECLINICAL STUDIES 17 May 2019 Pages: 329 - 339
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML Jae Yoon JeonQiuhong ZhaoBhavana Bhatnagar PHASE I STUDIES 17 May 2019 Pages: 340 - 349
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer Qing-Hua LiuHong-Mei YongJin Bai PRECLINICAL STUDIES 23 May 2019 Pages: 350 - 359
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer Bo Mi KuYeon Hee BaeMyung-Ju Ahn PRECLINICAL STUDIES Open access 24 May 2019 Pages: 360 - 368
Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines Joana JorgeSara PetronilhoAna Bela Sarmento-Ribeiro PRECLINICAL STUDIES 31 May 2019 Pages: 369 - 377
Anticancer activities of vitamin K3 analogues Kevin W. WellingtonVincent HlatshwayoLesetja R. Motadi PRECLINICAL STUDIES 07 November 2019 Pages: 378 - 391
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer Jeanetta StegaMarcus S. NoelSteve Hoffman PHASE I STUDIES Open access 30 March 2019 Pages: 392 - 401
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma C. EvenU. LassenChristophe Massard PHASE I STUDIES Open access 06 April 2019 Pages: 402 - 409
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer Takako Eguchi NakajimaNarikazu BokuYu Sunakawa PHASE I STUDIES 24 April 2019 Pages: 410 - 418
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors Geoffrey I. ShapiroPatricia LoRussoJohanna Bendell PHASE I STUDIES 24 April 2019 Pages: 419 - 432
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors Bin FanIngo K. MellinghoffDavid Dai PHASE I STUDIES Open access 26 April 2019 Pages: 433 - 444
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies Noboru YamamotoBaek-Yeol RyooToshihiko Doi PHASE I STUDIES 30 April 2019 Pages: 445 - 456
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma Emilie M. J. van BrummelenEvgeny LevchenkoJosé Trigo PHASE I STUDIES 07 May 2019 Pages: 457 - 467
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours Takahiro EbataToshio ShimizuNoboru Yamamoto PHASE I STUDIES Open access 24 May 2019 Pages: 468 - 477
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC Meijuan HuangYouling GongYou Lu PHASE I STUDIES 24 June 2019 Pages: 478 - 484
Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy Tomoharu YoshiyaTakahiro MimaeMorihito Okada PHASE II STUDIES 19 August 2019 Pages: 485 - 492
Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor Heejung ChaeMin-Hee RyuYoon-Koo Kang PHASE II STUDIES 18 October 2019 Pages: 493 - 499
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma Jian ZhaoJunmei LeiSuxiang Zhang PHASE II STUDIES Open access 24 October 2019 Pages: 500 - 506
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial Jun CaoQuchang OuyangXichun Hu PHASE III STUDIES 08 February 2020 Pages: 507 - 514
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer Xiaofeng GongDanyu DuShengtao Yuan Review 01 February 2020 Pages: 515 - 524
Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor Jia LiuDongwei XueYili Liu SHORT REPORT 10 June 2019 Pages: 525 - 532
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis Masashi IshikawaSatoru IwasaNarikazu Boku SHORT REPORT 02 July 2019 Pages: 533 - 540
Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls Gabriel DaraganJenny HoffmannPatrick Ziegler SHORT REPORT 11 July 2019 Pages: 541 - 545